Ionis Pharmaceuticals: A Rare Milestone and the Strategic Shift in Neurology - Experts See 98% Share Price Potential!
Reading Time: 3 minutes
The FDA approval for Zanvastro, 19 days before the PDUFA date, opens the door to an untapped market for a rare neurological disease. H.C. Wainwright reaffirms the Buy rating with a target price of $115, implying significant upside potential. The potential monetization of a Priority Review Voucher worth approximately $200 million strengthens the financial foundation for future developments. Pioneer of RNA Therapies on the Path to Independence Ionis Pharmaceuticals (IONS) focuses on the development of RNA-targeted therapeutics for the treatment...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
